In this model of postmenopausal arthritis, YSJB administration improved arthritis progression and prevented bone destruction by reducing osteoclastogenesis and regulating the expression of ephrinB2, ephB4, and NFATc1 in the BM. This evidence concerns the gene NFATC1 and arthritic joint disease.